Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2018-08-17 Major Shareholding Noti…
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification
2018-08-17 English
AMENDMENT NO. 1 TO THE SCHEDULE 13G
Major Shareholding Notification
2018-08-10 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, reporting the financial results for the quarter ended June 30, 2018. It references a press release titled 'Protagonist Therapeutics Reports Second Quarter 2018 Financial Results' as an exhibit. The document itself is short (3656 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. Therefore, the appropriate classification is ER with high confidence.
2018-08-07 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus related to a common stock offering by Protagonist Therapeutics, Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, capitalization, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act. The content focuses on the offering of shares and warrants, terms of the offering, and related disclosures, which are typical of capital raising documents. There is no indication of financial statements, audit reports, earnings releases, or management discussions. The document is not a report publication announcement but the actual offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-08-07 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2018, by Protagonist Therapeutics, Inc. It reports the entry into a material definitive agreement involving the sale of common stock and warrants, describing the terms of the securities purchase agreement and private placement. The content focuses on financing activities, including share issuance and warrant details, and references registration rights and related agreements. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, management report, or governance document. The primary subject is the company's capital raising transaction. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (7053 characters) supports it being a substantive filing rather than a brief announcement or certification.
2018-08-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.